

LETTER OF APPROVAL / RECOMMENDATION

To,

The Coordinator, Mediwheel (Arcofemi Healthcare Limited) Helpline number: 011-41195959

Dear Sir / Madam,

Sub: Annual Health Checkup for the employees of Bank of Baroda

This is to inform you that the following employee wishes to avail the facility of Cashless Annual Health Checkup provided by you in terms of our agreement.

Annual Health Checkup provided #7.7	
TO COLUMN TO COLUMN A FOR	EMPLOYEE DETAILS
PARTICULARS	MRS. GARG NANCY
NAME	120738
EC NO.	SINGLE WINDOW OPERATOR A
50.0.0	GHAZIABAD,VIJAY NAGAR
PLACE OF WORK	30-11-1991
	29-03-2024
PROPOSED DATE OF HEALTH	
CHECKUP	23M120738100100314E
BOOKING REFERENCE NO.	Leavest and the second of the

This letter of approval / recommendation is varid if submitted along with copy of the Bank of Baroda employee id card. This approval is valid from 14-03-2024 till 31-03-2024. The list of medical tests to be conducted is provided in the annexure to this letter. Please note that the said health checkup is a cashless facility as per our tie up arrangement. We request you to attend to the health checkup requirement of our employee and accord your top priority and best resources in this regard. The EC Number and the booking reference number as given in the above table shall be mentioned in the invoice, invariably.

We solicit your co-operation in this regard.

Yours faithfully,

Sd/-

Chief General Manager HRM Department Bank of Baroda

(Note: This is a computer generated letter, No Signature required. For any clarification, please contact Mediwheel (Arcefemi Healthcare Limited))











नैन्सी गर्ग Nancy Garg जन्म तिथि / DOB : 30/11/1991 महिला / Female





5806 4790 2617

मेरा आधार, मेरी पहचान

Mal health John



आरतीय विशिष्ट पहुंचान प्राचिकरण



पताः तुषार संगल, ए४ 1506 चेर्रय काउंटी, घ 5बी टेचजोंने ४, एकमुरति चोट्क, ग्रेटर नोएडा वेस्ट, नॉएडा सेक्टर 34, गौतमबुद्ध नगर, उत्तर प्रदेश, 201307

Address: W/O Tushar Sangal, A4 1506
Cherry County, Gh 5b Techzone 4, Ekmurti
Chowk, Greater Noida West, Noida Sector
34, Gautam Buddha Nagar, Uttar Pradesh,
201307



5806 4790 2617











NAME	MRS Nancy GARG	STUDY DATE	29/03/2024 9:36AM		
AGE / SEX	32 y / F	HOSPITAL NO.	MH010665579		
ACCESSION NO.	R7142553	MODALITY	CR /		
EPORTED ON 29/03/2024 9:44AM		REFERRED BY	HEALTH CHECK MGD		

XR- CHEST PA VIEW

FINDINGS:

LUNGS: Normal. TRACHEA: Normal. CARINA: Normal.

RIGHT AND LEFT MAIN BRONCHI: Normal.

PLEURA: Normal. HEART: Normal.

RIGHT HEART BORDER: Normal. LEFT HEART BORDER: Normal. PULMONARY BAY: Normal. PULMONARY HILA: Normal.

AORTA: Normal.

THORACIC SPINE: Normal.

OTHER VISUALIZED BONES: Normal. VISUALIZED SOFT TISSUES: Normal.

DIAPHRAGM: Normal.

VISUALIZED ABDOMEN: Normal. VISUALIZED NECK: Normal.

IMPRESSION:

No significant abnormality noted.

Recommend clinical correlation.

Dr. Monica Shekhawat MBBS, DNB

CONSULTANT RADIOLOGIST

Maria.

******End Of Report*****





NAME	MRS Nancy GARG	STUDY DATE	29/03/2024 10:06AM	
AGE / SEX	32 y / F	HOSPITAL NO.	MH010665579	
ACCESSION NO.	R7142554	MODALITY	US	
REPORTED ON	29/03/2024 10:31AM	REFERRED BY	HEALTH CHECK MGD	

USG ABDOMEN & PELVIS

FINDINGS

LIVER: appears enlarged in size (measures 152 mm) but normal in shape and shows diffuse increase in liver echotexture, in keeping with diffuse grade I fatty infiltration. Rest normal.

SPLEEN: Spleen is normal in size (measures 85 mm), shape and echotexture. Rest normal.

PORTAL VEIN: Appears normal in size and measures 9.1 mm.

COMMON BILE DUCT: Appears normal in size and measures 2.7 mm.

IVC, HEPATIC VEINS: Normal. BILIARY SYSTEM: Normal.

GALL BLADDER: Gall bladder is well distended. Wall thickness is normal and lumen is echofree. Rest normal.

PANCREAS: Pancreas is normal in size, shape and echotexture. Rest normal.

KIDNEYS: Bilateral kidneys are normal in size, shape and echotexture. Cortico-medullary differentiation is

maintained. Rest normal.

Right Kidney: rneasures 97 x 32 mm. Left Kidney: measures 98 x 42 mm. PELVI-CALYCEAL SYSTEMS: Compact.

NODES: Not enlarged. FLUID: Nil significant.

URINARY BLADDER: Urinary bladder is well distended. Wall thickness is normal and lumen is echofree. Rest

normal.

UTERUS: Uterus is anteverted, bulky in size (measures 98 x 47 x 42 mm) but normal in shape and shows coarse myometrial echotexture.

Endometrial thickness measures 2.8 mm. Cervix appears normal.

OVARIES: Both ovaries are normal in size, shape and echotexture. Rest normal.

Right ovary measures 31 x 30 x 16 mm with volume 7.7 cc.

Left ovary measures 30 x 29 x 15 mm with volume 6.7 cc.

BOWEL: Visualized bowel loops appear normal.

IMPRESSION

- -Hepatomegaly with diffuse grade I fatty infiltration in liver.
- -Bulky uterus with coarse myometrial echotexture.

Recommend clinical correlation.

Dr. Monica Shekhawat MBBS, DNB

CONSULTANT RADIOLOGIST

Maria.

*****End Of Report*****





Name

MRS NANCY GARG

Age

32 Yr(s) Sex :Female

Registration No

MH010665579

Lab No

202403004220

Patient Episode

H18000002002

Collection Date:

29 Mar 2024 09:21

Referred By

Receiving Date

HEALTH CHECK MGD 29 Mar 2024 09:21

Reporting Date: 29 Mar 2024 14:12

BIOCHEMISTRY

TEST

RESULT

UNIT

uIU/mL

BIOLOGICAL REFERENCE INTERVAL

[0.250 - 5.000]

THYROID PROFILE, Serum		Specimen Type : Serum
T3 - Triiodothyronine (ELFA)	1.070 ng/ml	[0.610-1.630]
T4 - Thyroxine (ELFA)	7.420 ug/dl	[4.680-9.360]

NOTE:

Thyroid Stimulating Hormone

TSH stimulates the thyroid gland to produce the main thyroid hormones T3 and T4. In cases of hyperthyroidism TSH level is severely inhibited and may even be undetectable. In rare forms of high-origin hyperthyroidism, the TSH level is not reduced, since the negative-feedback control of the thyroid hormone's has no effect.

1.120

In cases of primary hypothyroidism, TSH levels are always much higher than normal and thyroid hormone levels are low.

The TSH assay aids in diagnosing thyroid or hypophysial disorders.

The T4 assay aids in assessing thyroid function, which is characterized by a decrease in thyroxine levels in patients with hypothyroidism and an increase in patients with hyperthyroidism.

The test has been carried out in Fully Automated Immunoassay System VIDAS using ELFA (Enzyme Linked Fluorescence Assay) technology.

Page 1 of 2





Name

: MRS NANCY GARG

Age

32 Yr(s) Sex: Female

Registration No

MH010665579

Lab No

202403004220

Patient Episode

H18000002002

Collection Date:

29 Mar 2024 09:21

Referred By

HEALTH CHECK MGD

This report is subject to the to

Reporting Date: 29 Mar 2024 16:38

Receiving Date

29 Mar 2024 09:21

BLOOD BANK

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Blood Group & Rh Typing (Agglutination by gel/tube technique) Specimen-Blood

Blood Group & Rh typing

O Rh(D) Positive

Technical note:

ABO grouping and Rh typing is done by cell and serum grouping by microplate / gel technique.

Page 2 of 2

NOTE:

- Abnormal Values

-----END OF REPORT-----

Dr. Charu Agarwal **Consultant Pathologist**





Name

: MRS NANCY GARG

Age

32 Yr(s) Sex :Female

Registration No

: MH010665579

Lab No

202403004220

Patient Episode

: H18000002002

Collection Date:

29 Mar 2024 09:21

Referred By

: HEALTH CHECK MGD

Reporting Date:

29 Mar 2024 14:34

Receiving Date

: 29 Mar 2024 09:21

HAEMATOLOGY

TEST	RESULT	UNIT	BIOLOGICAL REFERENCE INT	TERVAL
COMPLETE BLOOD COUNT (AUTOMA:	TED)	SPECIMEN-ED	OTA Whole Blood	
RBC COUNT (IMPEDENCE) HEMOGLOBIN	4.17	millions/cu	[0.00 1.00]	
Method:cyanide free SLS-colo		ġ/dl	[12.0-15.0]	
HEMATOCRIT (CALCULATED) MCV (DERIVED) MCH (CALCULATED) MCHC (CALCULATED) RDW CV% (DERIVED) Platelet count Method: Electrical Impedance MPV (DERIVED)	38.7 92.8 29.7 32.0 13.2 282	% fL pg g/dl % x 10 ³ cells	[36.0-46.0] [83.0-101.0] [25.0-32.0] [31.5-34.5] [11.6-14.0] [150-410]	1
WBC COUNT (TC) (IMPEDENCE) DIFFERENTIAL COUNT (VCS TECHNOLOGY/MICROSCOPY)	6.72	x 10 ³ cells	[4.00-10.00]	
Neutrophils	48.0	90	[40.0-80.0]	
Lymphocytes	40.0	8	[20.0-40.0]	
Monocytes	6.0	90	[2.0-10.0]	
Eosinophils	6.0	%	[1.0-6.0]	
Basophils	0.0	ଚ	[0.0-2.0]	
ESR	21.0 #	mm/1sthour		-0.0]

Page 1 of 8





Name

: MRS NANCY GARG

Age

: 32 Yr(s) Sex :Female

Registration No

: MH010665579

Lab No

202403004220

Patient Episode

: H18000002002

Collection Date:

29 Mar 2024 09:21

Referred By

: HEALTH CHECK MGD

Reporting Date:

29 Mar 2024 16:31

Receiving Date

: 29 Mar 2024 09:21

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Glycosylated Hemoglobin

Specimen: EDTA

HbAlc (Glycosylated Hemoglobin)

5.1

[0.0-5.6]

Method: HPLC

As per American Diabetes Association (ADA

HbAlc in %

Non diabetic adults >= 18 years <5.7

Prediabetes (At Risk)5.7-6.4 Diagnosing Diabetes >= 6.5

Estimated Average Glucose (eAG)

100

mg/dl

Comments: HbAlc provides an index of average blood glucose levels over the past 8-12 weeks and is a much better indicator of long term glycemic control.

ROUTINE URINE ANALYSIS (Semi Automated) Specimen-Urine

MACROSCOPIC DESCRIPTION

Colour

PALE YELLOW

(Pale Yellow - Yellow)

Appearance

Reaction[pH]

SLIGHTLY TURBID 7.0

(4.6 - 8.0)

Specific Gravity

1.005

(1.003-1.035)

CHEMICAL EXAMINATION

Protein/Albumin

Negative

(NEGATIVE)

Glucose

NIL

(NIL)

Ketone Bodies

Negative

(NEGATIVE)

Urobilinogen

Normal

(NORMAL)

Page 2 of 8





Name

: MRS NANCY GARG

Age

32 Yr(s) Sex :Female

Registration No

: MH010665579

Lab No

202403004220

Patient Episode

: H18000002002

MICROSCOPIC EXAMINATION (Automated/Manual)

Collection Date:

29 Mar 2024 10:15

Referred By

: HEALTH CHECK MGD

Reporting Date:

29 Mar 2024 14:20

Receiving Date

: 29 Mar 2024 10:15

CLINICAL PATHOLOGY

Pus Cells RBC	8-10 /hpf		(0-5/hpf)	
Epithelial Cells	1-2 /hpf	- 6	(0-2/hpf)	
CASTS	2-4 /h; NIL	pī		
Crystals	NIL			
Bacteria	NIL			
OTHERS	NIL			
OTHERS	NTT			
Serum LIPID PROFILE				
Serum TOTAL CHOLESTEROL		155	mg/dl	[<200]
Method:Oxidase, esterase, per	oxide		97 0.2	Moderate risk:200-239
The second secon		e v		High risk:>240
TRIGLYCERIDES (GPO/POD)		72	mg/dl	[<150]
			170	Borderline high:151-199
				High: 200 - 499
				Very high:>500
HDL- CHOLESTEROL		49	mg/dl	[35-65]
Method: Enzymatic Immunoimh				
VLDL- CHOLESTEROL (Calculated	d)	14	mg/dl	[0-35]
CHOLESTEROL, LDL, CALCULATED		92.0	mg/dl	[<120.0]
				Near/
Above optimal-100-129				
				Borderline High: 130-159
				High Risk:160-189
T.Chol/HDL.Chol ratio(Calcui	lated)	3.2		<4.0 Optimal
				4.0-5.0 Borderline
				>6 High Risk
LDL.CHOL/HDL.CHOL Ratio(Calcu	ılated)	1.9		<3 Optimal
, , , , , , , , , , , , , , , , , , , ,	enverse en Electrica (fil		(4)	3-4 Borderline
				>6 High Risk
				magni Naok

Page 3 of 8





Name

: MRS NANCY GARG

Age

32 Yr(s) Sex: Female

Registration No

: MH010665579

Lab No

202403004220

Patient Episode

: H18000002002

Collection Date:

29 Mar 2024 09:21

Referred By

: HEALTH CHECK MGD

Receiving Date

: 29 Mar 2024 09:21

Reporting Date:

29 Mar 2024 14:12

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Note:

Reference ranges based on ATP III Classifications.

Lipid profile is a panel of blood tests that serves as initial broad medical screening tool for abnormalities in lipids, the results of this tests can identify certain genetic diseases and determine approximate risks for cardiovascular disease, certain forms of pancreatitis and other diseases

KIDNEY PROFILE

Icterus / Lipemia.

Specimen: Serum UREA	14.9	#	mg/dl	[15.0-40.0]
Method: GLDH, Kinatic assay BUN, BLOOD UREA NITROGEN Method: Calculated	7.0	#	mg/dl	[8.0-20.0]
CREATININE, SERUM Method: Jaffe rate-IDMS Standardization	0.58	#	mg/dl	[0.70-1.20]
URIC ACID Method:uricase PAP	3.8	#	mg/dl	[4.0-8.5]
*				
SODIUM, SERUM	137.50		mmol/L	[136.00-144.00]
POTASSIUM, SERUM	4.18		mmol/L	[3.60-5.10]
SERUM CHLORIDE Method: ISE Indirect	106.4		mmol/L	[101.0-111.0]
eGFR (calculated) Technical Note	122.4		ml/min/1.73sq.m	[>60.0]
eGFR which is primarily based on Serum	Creatini	ne is	a derivation of	CKD-EPI 2009

equation normalized to1.73 sq.m BSA and is not applicable to individuals below 18 years. eGFR tends to be less accurate when Serum Creatinine estimation is indeterminate e.g.

patients at extremes of muscle mass, on unusual diets etc. and samples with severe Hemolysis

Page 4 of 8





Name

: MRS NANCY GARG

Registration No

: MH010665579

Patient Episode

: H18000002002

Referred By Receiving Date : HEALTH CHECK MGD

: 29 Mar 2024 09:21

Age

32 Yr(s) Sex :Female

Lab No

202403004220

Collection Date:

29 Mar 2024 09:21

Reporting Date:

29 Mar 2024 14:12

BIOCHEMISTRY

TEST	RESULT	UNIT BIOLO	GICAL REFERENCE IN	TERVAL
8				
LIVER FUNCTION TEST				
BILIRUBIN - TOTAL	0.72	mg/dl	[0.30-1.20]	
Method: D P D				
BILIRUBIN - DIRECT Method: DPD	0.13	mg/dl	[0.00-0.30]	
INDIRECT BILIRUBIN (SERUM) Method: Calculation	0.59	mg/dl	[0.10-0.90]	
TOTAL PROTEINS (SERUM) Method: BIURET	6.60	gm/dl	[6.60-8.70]	
ALBUMIN (SERUM) Method: BCG	4.36	g/dl	[3.50-5.20]	
GLOBULINS (SERUM) Method: Calculation	2.20	gm/dl	[1.80-3.40]	
PROTEIN SERUM (A-G) RATIO Method: Calculation	1.95	W 2	[1.00-2.50]	
AST(SGOT) (SERUM) Method: IFCC W/O P5P	15.00	U/L	[0.00-40.00]	
ALT(SGPT) (SERUM) Method: IFCC W/O P5P	13.50 #	U/L	[14.00-54.00]	
Serum Alkaline Phosphatase Method: AMP BUFFER IFCC)	54.0	IU/L	[32.0-91.0]	
GGT	15.0	U/L	[7.0-50.0]	

Page 5 of 8





Name

: MRS NANCY GARG

Age

32 Yr(s) Sex :Female

Registration No

: MH010665579

Lab No

202403004220

Patient Episode

: H18000002002

Collection Date:

29 Mar 2024 09:21

Referred By

: HEALTH CHECK MGD

Reporting Date:

29 Mar 2024 14:12

Receiving Date

: 29 Mar 2024 09:21

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Liver function test aids in diagnosis of various pre hepatic, hepatic and post hepatic causes of dysfunction like hemolytic anemia's, viral and alcoholic hepatitis and cholestasis of obstructive causes.

The test encompasses hepatic excretory, synthetic function and also hepatic parenchymal cell damage. LFT helps in evaluating severity, monitoring therapy and assessing prognosis of liver disease and dysfunction.

Page 6 of 8

----END OF REPORT----

Dr. Charu Agarwal Consultant Pathologist

Chaery





Name

: MRS NANCY GARG

Registration No

: MH010665579

Patient Episode

: H18000002002

Referred By

: HEALTH CHECK MGD

Receiving Date

: 29 Mar 2024 09:21

Age

32 Yr(s) Sex :Female

Lab No

202403004221

Collection Date:

29 Mar 2024 09:21

Reporting Date :

29 Mar 2024 14:12

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

GLUCOSE-Fasting

Specimen: Plasma

GLUCOSE, FASTING (F)

100.0

mg/dl

[70.0-110.0]

Method: Hexokinase

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in Diabetes mellitus, Cushing's syndrome (10-15%), chronic pancreatitis (30%). Drugs corticosteroids, phenytoin, estrogen, thiazides

Decreased in Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortica insufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical, stomach, fibro sarcoma), infant of a diabetic mother enzyme deficiency diseases(e.g.galactosemia), orugs-

insulin, ethanol, propranolol, sulfonylureas, tobutamide, and other oral hypoglycemic agents.

Page 7 of 8

----END OF REPORT-

This report is subject to the terms and condition

Dr. Charu Agarwal Consultant Pathologist





Name

: MRS NANCY GARG

Registration No

: MH010665579

Patient Episode

: H18000002002

Referred By

: HEALTH CHECK MGD

Receiving Date

: 29 Mar 2024 13:24

Age

32 Yr(s) Sex :Female

Lab No

202403004222

Collection Date:

29 Mar 2024 13:24

Reporting Date:

29 Mar 2024 16:04

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

PLASMA GLUCOSE

Specimen:Plasma

GLUCOSE, POST PRANDIAL (PP), 2 HOURS

116.0

mg/dl

[80.0-140.0]

Method: Hexokinase

Note:

Conditions which can lead to lower postprandial glucose levels as compared to fasting glucose are excessive insulin release, rapid gastric emptying, brisk glucose absorption , post exercise

Page 8 of 8

-----END OF REPORT----

Dr. Alka Dixit Vats Consultant Pathologist

manipalhospitals





Patient Name

MRS NANCY GARG

Location

: Ghaziabad

Age/Sex

: 32Year(s)/Female

Visit No

: V000000001-GHZB

MRN No

MH010665579

Order Date

: 29/03/2024

Ref. Doctor

: DR BHUPENDRA SINGH

Report Date

: 29/03/2024

Protocol

: Bruce

MPHR

: 188BPM

Duration of exercise

: 5min 27sec

85% of MPHR

: 159BPM

Reason for termination : THR achieved

Peak HR Achieved : 168BPM

Blood Pressure (mmHg) : Baseline BP : 120/80mmHg

% Target HR

: 89%

Peak BP

: 150/90mmHg

METS

: 7.0METS

STAGE	TIME (min)	H.R (bpm)	BP (mmHg)	SYMPTOMS	ECG CHANGES	ARRHYTHMIA
		((19)			
PRE- EXC.	0:00	86	120/80	Nil	No ST changes seen	Nil
STAGE 1	3:00	143	140/90	Nil	No ST changes seen	Nil
STAGE 2	2:35	163	150/90	Nil	No ST changes seen	Nil
RECOVERY	4:24	94	130/80	Nil	No ST changes seen	Nil

COMMENTS:

- No ST changes in base line ECG.
- No ST changes at peak stage.
- No ST changes in recovery.
- Normal chronotropic response.
- Normal blood pressure response.

IMPRESSION:

Treadmill test is negative for exercise induced reversible myocardial ischemia.

Dr. Bhupendra Singh

MD, DM (CARDIOLOGY), FACC

Sr. Consultant Cardiology

Dr. Abhishek Singh

MD, DNB (CARDIOLOGY), MNAMS MD

Sr.Consultant Cardiology

Dr. Sudhanshu Mishra

Cardiology Registrar

Manipal Hospital, Ghaziabad

NH - 24, Hapur Road, Ghaziabad, Uttar Pradesh - 201 002

P: 0120-3535353

Manipal Health Enterprises Private Limited

CIN: U85110KA2003PTC033055

Regd. Off. The Annexe, #98/2, Rustom Bagh, Off. HAL Airport Road, Bengaluru - 560 017

P +91 80 4936 0300 F info@manihospitals.com www.manipalhospitals.com